ArticleFrontiers of medicine2019

Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl

Ruoxi Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.